Guardant Health loses key patent challenge as PTAB upholds all 30 TwinStrand patent claims
FROM THE WIRE · FINANCE.YAHOO.COM
Guardant Health (NasdaqGS:GH) lost a key U.S. patent challenge after the PTAB upheld all 30 claims of TwinStrand's '127 patent. The ruling centers on Duplex Sequencing technology and follows an earlier jury finding of willful patent infringement against Guardant Health. The…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishUpheld patent claims raise legal and royalty pressure on Guardant Health's use of Duplex Sequencing technology.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The PTAB upheld all 30 claims of TwinStrand's '127 patent.
- 02The ruling concerns Duplex Sequencing technology used by Guardant Health.
- 03It follows an earlier jury finding of willful patent infringement against Guardant Health.
- 04The decision supports ongoing royalties and payments to TwinStrand.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets